Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bela Patel

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Leukemia|August 26, 2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturationVilma Dembitz, Hannah Lawson, Richard Burt, et al.
JCI Insight|February 1, 2022
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infectionHan-Sol Park, Janna R Shapiro, Ioannis Sitaras, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2023
Early Treatment, Inflammation and Post-COVID ConditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Mbio|December 14, 2023
Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions"Kelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Mbio|September 19, 2023
Early antibody treatment, inflammation, and risk of post-COVID conditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Microbiology Spectrum|November 27, 2023
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trialFeben Habtehyimer, Xianming Zhu, Andrew D Redd, et al.
The Lancet. Microbe|September 2, 2023
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort studyXianming Zhu, Kelly A Gebo, Alison G Abraham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled TrialShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infectionShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Leukemia|August 26, 2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturationVilma Dembitz, Hannah Lawson, Richard Burt, et al.
JCI Insight|February 1, 2022
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infectionHan-Sol Park, Janna R Shapiro, Ioannis Sitaras, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2023
Early Treatment, Inflammation and Post-COVID ConditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Mbio|December 14, 2023
Erratum for Gebo et al., "Early antibody treatment, inflammation, and risk of post-COVID conditions"Kelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Mbio|September 19, 2023
Early antibody treatment, inflammation, and risk of post-COVID conditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Microbiology Spectrum|November 27, 2023
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trialFeben Habtehyimer, Xianming Zhu, Andrew D Redd, et al.
The Lancet. Microbe|September 2, 2023
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort studyXianming Zhu, Kelly A Gebo, Alison G Abraham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled TrialShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infectionShmuel Shoham, Evan M Bloch, Arturo Casadevall, et al.
Pageof 11